ClinicalTrials.gg
CompletedNCT02835534Updated May 25, 2022

The Efficacy and Safety of rhTNK-tPA in Comparison With Alteplase(Rt-PA) as Fibrinolytic Therapy of Acute STEMI

A Phase 4 interventional study of rhTNK-tPA and alteplase in Acute ST Elevation Myocardial Infarction, sponsored by Guangzhou Recomgen Biotech Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2022-05-25.

Sponsored by Guangzhou Recomgen Biotech Co., Ltd. (part of CSPC Pharmaceutical Group Limited) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
818
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 146 studies in ST Elevation Myocardial Infarction with a site in China — 41 open to participants now, 43 under way, 2 of them phase 3. ST Elevation Myocardial Infarction · China.

Enrollment
29th of 97
818 · median 320
Started
2016
with 5 others
Phase 4
25 of 146
4 open now
Registered
28th of 146
by date

Among the 146 studies in ST Elevation Myocardial Infarction with a site in China, this one is the 29th largest by enrollment of the 97 interventional ones that give a count, is one of 6 that started in 2016, is one of 25 in phase 4, and was the 28th registered.

ST Elevation Myocardial Infarction

852 studies on the registry are indexed under ST Elevation Myocardial Infarction; 198 are open to participants now.

Browse ST Elevation Myocardial Infarction studies →

Open to participants now

41 of the 146 studies in ST Elevation Myocardial Infarction with a site in China are open now. Recruiting first, the newest first:

36 more — sign in →

All 41 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 122 ST Elevation Myocardial Infarction studies recruiting now, 76 (62%) set no upper age limit and 20 (16%) stop at 75 or younger; 10 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 146 studies in ST Elevation Myocardial Infarction with a site in China, or all of them as a file.
02

Study summary

This study is aiming to test the hypothesis that efficacy of rhTNK-tPA was not inferior to rt-PA with respect to the 30-day MACCE rates after fibrinolytic therapy for STEMI patients. It is a multicenter, randomized, open, parallel, active-controlled, non-inferiority trial.

Read the detailed description

The study includes screening and baseline, randomization \& intervention, in-hospital visit, at 30±3 days visit after fibrinolytic therapy.

Following an initial eligibility screening assessment, all eligible patients who have signed the informed consent will be randomly assigned by an interactive Web-based central system for fibrinolytic therapy with either rhTNK-tPA or rt-PA. The standard care should be given to all patients except for the study interventions.

Prior to fibrinolytic administration, enoxaparin (30-mg intravenous) or Un- Fractionated Heparin (maximum 4000U, intravenous) should be administered, combined with antiplatelet therapy consisted of both clopidogrel and aspirin in a 300-mg loading dose followed by routine dosage.

Successful reperfusion according to the clinical evidence (EKG) should be assessed after fibrinolytic therapy.TIMI flow should be assessed for those patients with 24 hours coronary angiography.

MACCE and bleeding events should be followed up and documented during the study until 30 days after fibrinolytic therap. An independent adjudication committee will judge the major endpoint events.

03

Conditions studied

  • Acute ST Elevation Myocardial Infarction

Keywords

  • acute ST elevation myocardial infarction
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosis of acute STEMI(meet with both conditions):

    • Ischemic chest pain ≥30mins in duration
    • ST elevation ≥0.1 mV in two or more limb leads or ≥0.2 mV in two or more contiguous precordial leads
  2. Onset of continuous ischemic symptoms of STEMI ≤6 hours prior to randomisation
  3. Anticipated Delay to Performing Primary PCI >60mins,or time from hospital arrival to to balloon inflation >90mins
  4. Signed received prior to participation the study

Exclusion criteria

Exclusion Criteria:

  1. Non-ST-segment-elevation myocardial infarction or unstable angina
  2. Reinfacrtion
  3. Cardiacgenic shock
  4. Suspected aortic dissection
  5. New left bundle branch block in
  6. Absolute and relative for Fibrinolytic Therapy in STEMI(referred from 2015 China STEMI Management Guideline):

    • Severe uncontrolled hypertension (unresponsive to emergency Therapy,BPs > 180 mmHg and/or BPd > 110 mmHg)
    • Any prior ICH,stroke with unknown cause, Ischemic stroke within 3 months
    • Known structural cerebral vascular lesion, malignant intracranial neoplasm
    • Active bleeding, or bleeding diathesis, active peptic ulcer
    • Significant closed-head or facial trauma within 3 months
    • Intracranial or intraspinal surgery within 2 months
    • Recent internal bleeding within 4 weeks
    • Major surgery within 3 weeks, or Traumatic
    • Prolonged cardiopulmonary resuscitation (>10 minutes)
    • Noncompressible vascular punctures within 2 weeks
    • Current use of anticoagulant therapy
  7. Current or with a history of significant diseases:

    • Damage to the central nervous system
    • Severe renal or hepatic dysfunction, blood system diseases,
    • Present with cardiac rupture evidence
    • Acute pericarditis,Subacute bacterial endocarditis, Septic thrombophlebitis or occluded AV cannula at seriously infected site
    • High likelihood of left heart thrombus, e.g., mitral stenosis with atrial fibrillation
    • Diabetic hemorrhagic retinopathy or other hemorrhagic ophthalmic conditions
    • History of PCI or coronary artery bypass graft(CABG)within 1 month
  8. Administration of fibrinlytic therapy prior to participation
  9. Weight below 50 kg
  10. Known current histroy of fall-down accident
  11. Any other unfavourable conditions for participation:

    • Known participation in other clinical trials
    • Known to allergic to rhTNK-tPA or tPA or relevant vehicle
    • Pregnancy or lactation
    • Mental disorder
    • Present with any unsuitable conditions for participation or completion of the study at the discretion of their treating physician
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
818 participants (actual)

Study arms

  • Experimental
    rhTNK-tPA

    rhTNK-tPA; Dose:16mg; Mode of admin: Single bolus Dose:50mg; Enoxaparin or unfractionated heparin for anticoagulant therapy, clopidogrel and aspirin for antiplatelet therapy before fibrinolytic therapy.

    Drug: rhTNK-tPA

  • Active comparator
    rt-PA

    Drug:alteplase;Dose:50mg; Mode of admin: administered as an 8-mg initial IV bolus followed by an infusion of 42 mg over the next 90 minutes Enoxaparin or unfractionated heparin for anticoagulant therapy, clopidogrel and aspirin for antiplatelet therapy before fibrinolytic therapy.

    Drug: alteplase

Interventions

  • Dose:16mg; Mode of admin: Single bolus Enoxaparin or unfractionated heparin for anticoagulant therapy, clopidogrel and aspirin for antiplatelet therapy before fibrinolytic therapy.

    Also known as: Recombinant Human TNK Tissue-type Plasminogen Activator

  • Dose:50mg; Mode of admin: administered as an 8-mg initial IV bolus followed by an infusion of 42 mg over the next 90 minutes Enoxaparin or unfractionated heparin for anticoagulant therapy, clopidogrel and aspirin for antiplatelet therapy before fibrinolytic therapy.

    Also known as: rt-PA

06

What researchers measure

Primary outcomes

  1. The proportion of patients with TIMI grade 2 or 3 flow in the infarct-related artery after therapy (Limited to the subgroup for coronary angiography within 24 hours after therapy)

    A patent IRA was defined as TIMI grade 2 or 3 flow on the angiogram

    Time frame: within 24 hours after therapy

Secondary outcomes

  1. The rate of MACCE (Major Adverse Cardiovascular and Cerebrovascular Events)

    MACCE composited of total death, non-fatal recurrent MI, non-fatal stroke (ischemic and Hemorrhage), PCI for failed reperfusion and PCI for reocclusion

    Time frame: within 30 days after the start of fibrinolytic therapy

  2. The rate of successful reperfusion with clinical evidences

    Time frame: within 24 hours of fibrinolytic therapy

  3. The in-hospital MACCE

    Time frame: during hospitalization (from the date of admission to the date of discharge, assessed up to 1 month)

  4. The in-hospital and 30-day all-cause mortality

    Time frame: during hospitalization (from the date of admission to the date of discharge, assessed up to 1 month) and 30 days after the start of study interventions

  5. The in-hospital and 30-day cardiac deaths

    Time frame: during hospitalization (from the date of admission to the date of discharge) and 30 days after the start of study interventions, assessed up to 1 month

  6. The in-hospital recurrent MI

    Time frame: during hospitalization (from the date of admission to the date of discharge, assessed up to 1 month)

  7. The 30-day revascularization

    Time frame: 30 days after the start of therapy

  8. The in-hospital intracranial hemorrhage (ICH)

    Time frame: during hospitalization (from the date of admission to the date of discharge, assessed up to 1 month)

  9. The in-hospital major GI bleeding events

    Time frame: during hospitalization (from the date of admission to the date of discharge, assessed up to 1 month)

  10. The in-hospital total bleeding events

    Time frame: during hospitalization (from the date of admission to the date of discharge, assessed up to 1 month)

Other outcomes

  1. The frequency and severity of AEs

    Time frame: during hospitalization (from the date of admission to the date of discharge, assessed up to 1 month)

  2. Medical cost within the initial hospitalization

    Time frame: from the date of admission to the date of discharge, assessed up to 1 month

  3. The frequency of re-hospitalizations and emergency room visits

    Time frame: at 30 days after therapy

07

Study locations

1 site
  • Guangzhou Recomgen Biotech Co., Ltd.
    Guangzhou, Guangdong 510530, China
08

References and documents

Publications

  • Wang HB, Ji P, Zhao XS, Xu H, Yan XY, Yang Q, Yao C, Gao RL, Wu YF, Qiao SB. Recombinant human TNK tissue-type plasminogen activator (rhTNK-tPA) versus alteplase (rt-PA) as fibrinolytic therapy for acute ST-segment elevation myocardial infarction (China TNK STEMI): protocol for a randomised, controlled, non-inferiority trial. BMJ Open. 2017 Sep 18;7(9):e016838. doi: 10.1136/bmjopen-2017-016838. PubMed 28928186 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2016 to primary completion in Oct 2019, 41 months.

Of 49 phase 4 interventional studies under ST Elevation Myocardial Infarction, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 63. This study's 41 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 12, 2016
First posted
Jul 18, 2016
StartActual
May 2016
Primary completionActual
Oct 2019
CompletionActual
Jan 2020
Last update
May 25, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 25, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02835534
Responsible party
Sponsor
First posted
Jul 18, 2016
Start date
May 2016
Primary completion
Oct 2019
Completion
Jan 2020
Last update
May 25, 2022

Study contacts

Shubin Qiaos, MD
principal investigator · Chinese Academy of Medical Sciences, Fuwai Hospital
Qin Yang, MD
study director · Guangzhou Recomgen Biotech Co., Ltd.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tenecteplase

Start the discussion